In this regard, circulating tumor DNA (ctDNA) can act as a genomic surrogate for tumor and has been investigated as an early diagnostic biomarker for PDAC, given that >90% of tumors harbor a KRAS mutation. This evidence concerns the gene KRAS and neoplasm.